NYSE:ADCT ADC Therapeutics (ADCT) Stock Price, News & Analysis $1.36 +0.04 (+2.65%) As of 09:50 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ADC Therapeutics Stock (NYSE:ADCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADC Therapeutics alerts:Sign Up Key Stats Today's Range$1.32▼$1.3250-Day Range$0.96▼$1.3752-Week Range$0.78▼$4.98Volume2,763 shsAverage Volume1.32 million shsMarket Capitalization$172.99 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity. At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S. Food and Drug Administration for the treatment of adults with relapsed or refractory large B-cell lymphoma. In addition to this approved asset, the company’s pipeline features multiple next-generation ADC candidates targeting novel antigens, several of which are advancing through late-stage clinical trials. Founded in 2012 as a spin-out from Heidelberg University, ADC Therapeutics is headquartered in Lausanne, Switzerland, with additional offices in London and New York. Its global footprint spans Europe and North America, encompassing clinical research sites and manufacturing partnerships that support multi-regional trials and scaled production of its specialized conjugates. The company is led by a management team with deep expertise in antibody engineering, oncology drug development and regulatory affairs. Through collaborations with academic institutions and industry partners, ADC Therapeutics seeks to accelerate its translational research efforts and bring innovative ADC therapies to patients battling blood cancers.AI Generated. May Contain Errors. Read More ADC Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreADCT MarketRank™: ADC Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 666th out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingADC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialADC Therapeutics has a consensus price target of $5.00, representing about 277.4% upside from its current price of $1.33.Amount of Analyst CoverageADC Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about ADC Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ADC Therapeutics are expected to grow in the coming year, from ($0.80) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ADC Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.10% of the float of ADC Therapeutics has been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in ADC Therapeutics has recently increased by 21.28%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for ADC Therapeutics this week, compared to 2 articles on an average week.Search Interest8 people have searched for ADCT on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows1 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.10% of the stock of ADC Therapeutics is held by insiders.Percentage Held by Institutions41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADC Therapeutics' insider trading history. Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADCT Stock News HeadlinesADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference2 hours ago | prnewswire.comBrokerages Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $5.00August 23, 2026 | americanbankingnews.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.September 3 at 1:00 AM | Investors Alley (Ad)ADC Therapeutics (ADCT) Q2 2026 Earnings Call TranscriptAugust 20, 2026 | finance.yahoo.comADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta OutlookAugust 16, 2026 | finance.yahoo.comADC Therapeutics SA (ADCT) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | seekingalpha.comADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ...August 14, 2026 | finance.yahoo.comADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational UpdatesAugust 13, 2026 | prnewswire.comSee More Headlines ADCT Stock Analysis - Frequently Asked Questions How have ADCT shares performed this year? ADC Therapeutics' stock was trading at $3.54 at the start of the year. Since then, ADCT stock has decreased by 62.6% and is now trading at $1.3250. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) announced its earnings results on Thursday, August, 13th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.11. The business earned $19.25 million during the quarter, compared to analysts' expectations of $18.89 million. Read the conference call transcript. When did ADC Therapeutics IPO? ADC Therapeutics (ADCT) raised $208 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 12,245,631 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO. Who are ADC Therapeutics' major shareholders? ADC Therapeutics' top institutional investors include Revolve Wealth Partners LLC (0.08%) and AXQ Capital LP (0.02%). Insiders that own company stock include Redmile Group, Llc, Ameet Mallik and Robert Azelby. View institutional ownership trends. How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADC Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/13/2026Today9/03/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ADCT's financial health is in the Red zone, according to TradeSmith. ADCT has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ADCT CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees310Year Founded2010Price Target and Rating Average Price Target for ADC Therapeutics$5.00 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+277.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$142.62 million Net Margins-121.77% Pretax Margin-122.28% Return on EquityN/A Return on Assets-32.74% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio2.97 Sales & Book Value Annual Sales$81.36 million Price / Sales2.08 Cash FlowN/A Price / Cash FlowN/A Book Value($1.79) per share Price / Book-0.74Miscellaneous Outstanding Shares127,670,000Free Float121,157,000Market Cap$169.16 million OptionableOptionable Beta1.84 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NYSE:ADCT) was last updated on 9/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
